Oncorus

67 articles with Oncorus

• Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  3/24/2023

  Oncorus, Inc. today reported fourth quarter and full year 2022 financial results and provided an update on its business.

• Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

  1/4/2023

  Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.

• Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

  11/30/2022

  Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeline to focus on its lead viral RNA (vRNA) immunotherapy product candidate, ONCR-021.

• Oncorus to Participate in Upcoming Investor Conferences

  11/23/2022

  Oncorus, Inc.today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences.

• Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

  11/18/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the presentation of preclinical data for ONCR-719 in a poster at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 17-20, 2022 in Tampa, Florida.

• Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/2/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported financial results for the third quarter of 2022 and highlighted recent achievements and developments.

• Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

  10/7/2022

  Oncorus, Inc. (Nasdaq: ONCR) today announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA (vRNA)/lipid nanoparticle (LNP) platform as a novel approach to treating cancer by enabling repeat intravenous (IV) administration of viral immunotherapy.

• Oncorus Appoints Douglas Fambrough to Board of Directors

  6/23/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.

• Oncorus to Present at the Jefferies Global Healthcare Conference - June 01, 2022

  6/1/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 3:30 p.m. ET in New York, NY.

• Oncorus to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference.

• 

  BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More

  5/13/2022

  Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.

• Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

  5/10/2022

  Oncorus, Inc., a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, announced the appointment of Richard Wanstall as Chief Financial Officer.

• Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

  5/4/2022

  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported first quarter 2022 financial results and highlighted recent achievements and developments.

• Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway

  4/5/2022

  Oncorus, Inc. announced that it has entered into a loan and security agreement with K2 HealthVentures, a healthcare focused specialty finance company.

• Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference

  3/21/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET.

• Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference

  3/10/2022

  Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:40 p.m. ET.

• Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/9/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported fourth quarter and full year 2021 financial results and highlighted recent achievements and developments.

• Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer

  2/22/2022

  Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced the promotion of John Goldberg, M.D. to Chief Medical Officer.

• Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

  1/3/2022

  Oncorus, Inc. today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.

• Oncorus to Present at Upcoming Investor Conferences

  11/23/2021

  Oncorus, Inc. today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference.